Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The effect of ferric citrate on IV iron, ESA utilization and laboratory parameters in real-world dialysis practice

Trial Profile

The effect of ferric citrate on IV iron, ESA utilization and laboratory parameters in real-world dialysis practice

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ferric citrate (Primary)
  • Indications Hyperphosphataemia; Iron deficiency anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Nov 2017 New trial record
    • 04 Nov 2017 According to a Keryx Biopharmaceuticals media release, data from this study were presented at the American Society of Nephrologys (ASN) 2017 Kidney Week.
    • 04 Nov 2017 Results presented in a Keryx Biopharmaceuticals Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top